Key takeaway: Neuland Laboratories Limited's investor presentation for Q1 FY27 reported a total income of Rs. 650.1 crore, reflecting a 116.3% year-over-year increase. EBITDA reached Rs. 231.1 crore, up 448.2% YoY, with an EBITDA margin of 35.5%, an increase of 2150 basis points. The profit after tax (PAT) was Rs. 147.4 crore, marking a 975.0% increase YoY. Management highlighted strong performance in both Contract Development and Manufacturing Organization (CDMO) and Generic Drug Substance (GDS) segments, with significant contributions from commercial products. The presentation noted a decrease in working capital days from 137 days in Q4 FY26 to 84 days in Q1 FY27, attributed to reduced receivables. Management emphasized ongoing investments and the strengthening of customer relationships, indicating a focus on long-term partnerships and consistent delivery.

Key takeaway: Neuland Laboratories Limited conducted its Q4 and FY26 earnings conference call on May 12, 2026, where management provided an overview of the financial performance. Total income for Q4FY26 was reported at INR788.7 crores, a 134.9% increase from INR335.8 crores in the same period last year, primarily driven by commercial CMS projects. The gross margin improved to 62.1% from 56.3% in Q4FY25, with EBITDA at INR319.4 crores and a margin of 40.5%. For FY26, revenue reached INR2053.1 crores, up 37.1% year-on-year. Management highlighted a focus on cash flow and working capital, noting a negative free cash flow of INR49.4 crores due to higher working capital needs. They emphasized ongoing efforts in cost and process improvements to enhance profitability. The management also discussed the potential of their peptide business and the importance of execution discipline in navigating market volatility. Overall, the call reflected a strong performance amid inherent business variability.

Key takeaway: Neuland Laboratories Limited submitted an investor presentation detailing its financial results for the quarter and year ended March 31, 2026. Management expressed satisfaction with the company's performance, highlighting strong business visibility and growth driven by commercial and near-commercial molecules. The presentation reported significant financial metrics, including a total income of Rs. 788.7 crore for Q4FY26, representing a 134.9% year-over-year increase, and an EBITDA of Rs. 319.4 crore, up 448.6% year-over-year. The EBITDA margin improved to 40.5%, while PAT reached Rs. 212.5 crore, reflecting a 666.3% increase. The company also noted a reduction in working capital days and a net debt of Rs. (156.8) crore. Key business strategies include investments in peptide manufacturing and a new R&D center, aimed at supporting sustainable growth.

Key takeaway: Neuland Laboratories Limited conducted its Q3FY26 earnings conference call on February 9, 2026, where management provided an overview of the financial results for the quarter and nine months ended December 31, 2025. Total income for Q3FY26 was reported at INR447.8 crores, reflecting an 11.4% year-on-year increase. The gross margin for the quarter was 52.1%, slightly down from 53.2% in the previous year, attributed to product mix variations. EBITDA was INR85 crores with a margin of 19%, impacted by increased overheads, including INR10 crores related to labor codes. Management noted a focus on optimizing working capital, which stood at 145 days of sales. The call highlighted ongoing investments in capacity expansion and the transition towards a more complex product portfolio, particularly in the CDMO space. Management expressed optimism about future growth, emphasizing the importance of long-term strategic planning and customer engagement.

Key takeaway: The investor presentation from Neuland Laboratories Limited, dated February 9, 2026, provided an overview of the company's financial results for the quarter and nine months ended December 31, 2025. Management reported total income of Rs. 447.8 crore for Q3FY26, reflecting an 11.4% year-over-year increase, while EBITDA decreased by 6% to Rs. 85 crore, resulting in an EBITDA margin of 19.0%. The presentation highlighted a significant decline in PAT, which fell 60% to Rs. 40.4 crore. Management noted that the product mix and increased operating expenses contributed to subdued EBITDA margins. The company experienced good momentum in business, with increasing interest from customers in its capabilities as a commercial NCE drug substance manufacturer. The presentation also detailed ongoing investments and strategic shifts towards higher-margin segments, particularly in CMS and Specialty businesses.